Change in plasma cytokine levels during risperidone treatment in children with autism

Journal of Child and Adolescent Psychopharmacology

Volumn 24, Issue 10, 2014, Pages 586-589

  Choi, Jae Eun ^a   Widjaja, Felicia ^b   Careaga, Milo ^c   Bent, Stephen ^b   Ashwood, Paul ^c   Hendren, Robert L ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA2 INTERFERON; BRAIN DERIVED NEUROTROPHIC FACTOR; CYTOKINE; EOTAXIN; GAMMA INTERFERON; GAMMA INTERFERON INDUCIBLE PROTEIN 10; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 10; INTERLEUKIN 12P40; INTERLEUKIN 12P70; INTERLEUKIN 13; INTERLEUKIN 15; INTERLEUKIN 17; INTERLEUKIN 2; INTERLEUKIN 5; INTERLEUKIN 6; INTERLEUKIN 7; INTERLEUKIN 8; LYMPHOTOXIN; MONOCYTE CHEMOTACTIC PROTEIN 1; RISPERIDONE; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA; NEUROLEPTIC AGENT;

ADULT; ARTICLE; AUTISM; CHILD; CLINICAL ARTICLE; DRUG DOSE TITRATION; DRUG MEGADOSE; FEMALE; HUMAN; MALE; OPEN STUDY; PROTEIN BLOOD LEVEL; TREATMENT DURATION; TREATMENT RESPONSE; ADOLESCENT; AUTISTIC DISORDER; BLOOD; CLINICAL TRIAL; PRESCHOOL CHILD;

ADOLESCENT; ANTIPSYCHOTIC AGENTS; AUTISTIC DISORDER; CHILD; CHILD, PRESCHOOL; CYTOKINES; FEMALE; HUMANS; MALE; RISPERIDONE;

EID: 84913598148     PISSN: 10445463     EISSN: 15578992     Source Type: Journal    
DOI: 10.1089/cap.2013.0108     Document Type: Article

References (20)

1. American Psychiatric Association: Diagnostic and Statistical Manual of Mental Disorders, 4th ed. Washington, DC: American Psychiatric Association; 1994
2. Ashwood P, Krakowiak P, Hertz-Picciotto I, Hansen R, Pessah IN, Van de Water J: Altered T cell responses in children with autism. Brain Behav Immunol 25: 840-849, 2011a
3. Ashwood P, Krakowiak P, Hertz-Picciotto I, Hansen R, Pessah IN, Van de Water J: Associations of impaired behaviors with elevated plasma chemokines in autism spectrum disorders. J Neuroimmunol 232: 196-199, 2011b
4. Ashwood, P, Wills, S and Van De Water, J: The immune response in autism: A new frontier for autism research. J Leukoc Biol 80: 1-15, 2006
5. Bent S, Bertoglio K, Ashwood P, Bostrom A, Hendren RL: A pilot randomized controlled trial of omega-3 fatty acids for autism spectrum disorder. J Autism Dev Disord 41: 545-554, 2011
6. Chen ML, Tsai TC, Wang LK, Lin YY, Tsai YM, Lee MC, Tsai FM: Risperidone modulates the cytokine and chemokine release of dendritic cells and induces TNF-A-directed cell apoptosis in neutrophils. Int Immunopharmacol 12: 197-204, 2012
7. Drzyzga L, Obuchowicz E, Marcinowska A, Herman ZS: Cytokines in schizoprenia and the effects of antipsychotic drugs. Brain Behav Immun 20: 532-545, 2006
8. Enstrom AM, Onore CE, Van de Water JA, Ashwood P: Differential monocyte responses to TLR ligands in children with autism spectrum disorders. Brain Behav Immunol 24: 64-71, 2010
9. Gupta S, Aggarwal S, Rashanravan B, Lee T: Th1-And Th2-like cytokines in CD4 + and CD8 + T cells in autism. J Neuroimmunol 85: 106-109, 1998
10. Himmerich H, Schönherr J, Fulda S, Sheldrick AJ, Bauer K, Sack U: Impact of antipsychotics on cytokine production in-vitro. J Psychiatr Res 45: 1358-1365, 2011
11. Lit L, Sharp FR, Bertoglio K, Stamova B, Ander BP, Sossong AD, Hendren RL: Gene expression in blood is associated with risperidone response in children with autism spectrum disorders. Pharmacogenomics J 12: 368-371, 2012
12. McCracken JT, McGough J, Shah B, Cronin P, Hong D, Aman MG, Arnold LE, Lindsay R, Nash P, Hollway J, McDougle CJ, Posey D, Swiezy N, Kohn A, Scahill L, Martin A, Koenig K, Volkmar F, Carroll D, Lancor A, Tierney E, Ghuman J, Gonzalez NM, Grados M, Vitiello B, Ritz L, Davies M, Robinson J, McMahon D; Research Units on Pediatric Psychopharmacology Autism Network: Risperidone in children with autism and serious behavioral problems. N Engl J Med 347: 314-321, 2002
13. Mundo E, Altamura AC, Vismara S, Zanardini R, Bignotti S, Randazzo R, Montresor C, Gennarelli M: MCP-1 gene (SCYA2) and schizophrenia: a case-control association study. Am J Med Genet B Neuropsychiatr Genet 132B: 1-4, 2005
14. Myers SM, Johnson, CP: Management of children with autism spectrum disorders. Pediatrics 120, 1162-1182, 2007
15. Na KS, Jung HY, Kim YK: The role of pro-inflammatory cytokines in the neuroinflammation and neurogenesis of schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry 48: 277-286, 2014
16. Onore C, Careaga M, Ashwood P: The role of immune dysfunction in the pathophysiology of autism. Brain Behav Immunol 26: 383-92, 2012
17. Teixeira AL, Reis HJ, Nicolato R, Brito-Melo G, Correa H, Teixeira MM, Romano-Silva MA: Increased serum levels of CCL11/eotaxin in schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry 32: 710-714, 2008
18. Thompson JR: Invited commentary. Re: Multiple comparisons and related issues in the interpretation of epidemiologic data Am J Epidemiol 147: 801-806, 1998
19. Tobiasova Z, van der Lingen KH, Scahill L, Leckman JF, Zhang Y, Chae W, McCracken JT, McDougle CJ, Vitiello B, Tierney E, Aman MG, Arnold LE, Katsovich L, Hoekstra PJ, Volkmar F, Bothwell AL, Kawikova I: Risperidone-related improvement of irritability in children with autism is not associated with changes in serum of epidermal growth factor and interleukin-13. J Child Adolesc Psychopharmacol 21: 555-564, 2011
20. Vargas DL, Nascimbene C, Krishnan C, Zimmerman AW, Pardo CA: Neuroglial activation and neuroinflammation in the brain of patients with autism. Ann Neurol 57: 67-81, 2005